Polymorphisms in angiogenesis pathway genes associated with tumor recurrence in surgery treated cancer patients
OwnerHeinz-Josef Lenzinventor
Life of this patent
Estimating the term…
Abstract
This invention provides compositions and methods for determining the likely tumor recurrence of cancer patients after surgical resection. Said methods are based on determining the patient's genotype for the polymorphisms PAR-1-506 ins/del and/or EGF+61 A>G.
Claims21
A method for identifying a cancer patient as likely or not likely to experience tumor recurrence, comprising determining a genotype of a cell or tissue sample isolated from the patient for at least one polymorphism of the group PAR-1-506 ins/del or EGF+61 A>G, wherein a genotype of at least one of:
- (a) (ins/ins or del/ins) for PAR-1-506 ins/del;
- or
- (b) (A/A) for EGF+61 A>G,
- identifies the patient as likely to experience tumor recurrence, or a genotype of neither (a) nor (b) identifies the patient as not likely to experience tumor recurrence.
A method for identifying a cancer patient as more likely or less likely to experience tumor recurrence, comprising determining a genotype of a cell or tissue sample isolated from the patient for at least one polymorphism of the group PAR-1-506 ins/del or EGF+61 A>G, wherein a genotype of at least one of:
- (a) (ins/ins or del/ins) for PAR-1-506 ins/del;
- or
- (b) (A/A) for EGF+61 A>G,
- identifies the patient as more likely to experience tumor recurrence as compared to a patient having a genotype of neither (a) nor (b) and having the cancer, or a genotype of neither (a) nor (b) identifies the patient as less likely to experience tumor recurrence as compared to a patient having a genotype of at least one of (a) or (b) and having the cancer.
A kit for use in determining if a cancer patient treated with surgery is likely to experience tumor recurrence, comprising suitable primers or probes or a microarray for determining at least one polymorphism of the group PAR-1-506 ins/del or EGF+61 A>G, and instructions for use therein.
A panel of probes or primers or a microarray for determining a genotype of a cell or tissue sample isolated from the patient for polymorphisms of the group PAR-1-506 ins/del and EGF+61 A>G.
Dependencies are inferred from the claim text.